Restrictive Lung Diseases: Archives News of the month
Exploring the mitigating potential of anthocyanin Malvidin in a mouse model of bleomycin-induced pulmonary fibrosis by inhibiting NLRP3 inflammasome activation and oxidative stress
Restrictive Lung Diseases 8 min.
Pulmonary fibrosis (PF) is a condition characterized by injury and scarring in the lungs, which makes breathing difficult due to the lung’s inability to carry oxygen to the bloodstream [1]. In PF, the normal lung tissue morphology was replaced by scar tissue, which may also lead to the accumulation...
Epidemiology of idiopathic pulmonary fibrosis in central and Western Pennsylvania
Restrictive Lung Diseases 4 min.
Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating disorder characterized by unremitting progressive scarring in the lung that leads to breathlessness, respiratory failure, and death [1, 2]. The estimates of the incidence of IPF have varied widely, depending on the case definitions,...
Telehealth in sarcoidosis: a scoping review
Restrictive Lung Diseases 6 min.
Sarcoidosis is a multisystem inflammatory disease of unknown etiology, posing significant challenges in diagnosis, treatment, and management for healthcare professionals. This disease, characterized by the formation of noncaseating granulomas in affected organs, can involve almost any organ in the body...
Evaluation of respiratory muscle dysfunction in patients with idiopathic pulmonary fibrosis: a prospective observational study with magnetic resonance imaging
Restrictive Lung Diseases 5 min.
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated median survival time of 3–5 years after diagnosis [1]. Patients with IPF are characterized by restrictive ventilatory dysfunction, progressively deteriorated exercise tolerance, impaired health-related quality...
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis
Restrictive Lung Diseases 8 min.
Over the past two decades, the paradigm of malignant tumor treatment has been revolutionized, which has been predominantly achieved by the advent of immune checkpoint inhibitors (ICIs) [1, 2, 3–4]. Despite the approval of numerous ICIs for a variety of malignancies, a majority of patients exhibit...
